Immortal Dragons, a Singapore‑based longevity investment fund, is increasing support for 3D biofabrication as a primary technological strategy to address age‑related organ failure. The company highlights the use of biocompatible “bio‑inks” that combine living cells with supportive materials to create functional tissues as part of its broader longevity investment thesis, according to the firm.
The fund’s emphasis on 3D biofabrication reflects a shift in the biotechnology investment landscape toward regenerative models that aim to intervene before chronic disease onset. The strategy targets technologies capable of producing engineered tissues and vascular structures that might replace failing biological components, offering alternatives to traditional synthetic grafts and donor organs.
Recent advances in bioengineered blood vessels have demonstrated improved integration and reduced thrombosis in large animal studies, underscoring potential clinical utility. Immortal Dragons’ support aligns with this progress and broader efforts to transition biofabrication innovations from research toward medical application.
The investment approach is informed by four pillars that include advancing scientific understanding, funding long‑term clinical development, influencing regulatory frameworks and shifting public perception of aging as a manageable process, according to the company.
Immortal Dragons currently supports more than 15 portfolio companies in longevity technologies and also engages in advocacy and educational initiatives to accelerate adoption of high‑impact biomedical advances.
